Effect of anti-VEGFR-3 treatment on hematopoietic reconstitution after allo-HSCT. Allo-HSCT recipients received intraperitoneal injections of 1 mg anti-VEGFR-3 antibody (mF4-31c1) or control antibody every second day from day 0 to day +10; 129/SV → C57BL/6, conditioning with Bu/Cy, allo-HSCT with 1.5 × 107 BM cells, 2 × 106 T cells. On day +11, allo-HSCT recipients were sacrificed, and organs were harvested for cell isolation and FACS analysis. (A-B) Chimerism was analyzed by staining of bone marrow cells (A) and blood cells (B) against Ly9.1 and H2kb (n = 4 per group). (C-J) Cell counts of immune cells in the blood of control antibody versus mF4-31c1–treated animals measured by flow cytometry (n = 4 per group). Error bars indicate mean ± SEM; significance was tested with an unpaired Student t test. TReg, regulatory T-cells.
